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[Abstract] Insulin resistance is a pathophysiological state defined by impaired responses to insulin and 
is a risk factor for several metabolic diseases, most notably type 2 diabetes. Insulin resistance occurs 
in insulin target tissues including liver, adipose and skeletal muscle. Methods such as insulin tolerance 
tests and hyperinsulinaemic-euglycaemic clamps permit assessment of insulin responses in specific 
tissues and allow the study of the progression and causes of insulin resistance. Here we detail a protocol 
for assessing insulin action in adipose and muscle tissues in anesthetized mice administered with insulin 
intravenously.  
Keywords: Insulin, Adipose tissue, Muscle, Glucose transport, Glucose uptake, Insulin tolerance test 
 
[Background] Surrogate measures of whole-body insulin sensitivity such as homeostatic model 
assessment for insulin resistance (HOMA-IR) often do not reflect insulin-stimulated glucose uptake in 
peripheral tissues of the mouse (Lee et al., 2008; Mather, 2009). Ex vivo adipose tissue explants or 
isolated skeletal muscles preparations (Burchfield et al., 2018; Fazakerley et al., 2018b) can allow direct 
measurement of insulin responses in specific tissues if they are amenable to these procedures, but do 
not preserve the organism environment where finely articulated delivery of glucose and insulin via the 
vasculature, uptake into cells and intracellular metabolism may all contribute to the overall rate of tissue 
glucose uptake (Wasserman et al., 2011). Commonly employed methods to assess whole-body insulin 
action in mice include intraperitoneal (IP) or intravenous insulin tolerance tests (ITTs) and, the gold 
standard, hyperinsulinaemic-euglycaemic clamp (Ayala et al., 2010; Brandon et al., 2016). These 
techniques can assess whole-body insulin action by measuring either changes in blood glucose (ITT) 
or changes in the amount of glucose required to maintain glycemia (glucose infusion rate; 
hyperinsulinaemic-euglycaemic clamp) and can be adapted to measure tissue-specific insulin 
responses. For example, glucose tracers such as radiolabeled 2-deoxyglucose (2-DOG), which is often 
used as a surrogate for glucose in assessing glucose uptake as it is not metabolized through glycolysis 
and is ‘trapped’ in the cells following uptake, can be introduced to permit assessment of glucose uptake 
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into specific tissues during these tests. Note that 2-DOG is only trapped in tissues that do not possess 
significant glucose-6-phosphatase activity, and so 2-DOG tracer is therefore not useful for assessing 
glucose disposal in the liver.  
  Both ITTs and hyperinsulinaemic-euglycaemic clamps can be performed in conscious or anesthetized 
mice. Certain anesthetics affect whole-body glucose metabolism and should therefore be avoided when 
assessing insulin action or glucose homeostasis [e.g., isoflurane (Pomplun et al., 2004; Tanaka et al., 
2009; Windelov et al., 2016; Hoyer et al., 2018)]. However, anesthetics that minimally affect glucose 
metabolism, such as pentobarbitone (Guarino et al., 2013), may actually be advantageous for studying 
insulin-stimulated glucose uptake. This is because insulin-stimulated 2-DOG/glucose uptake in 
conscious mice may be affected by movement (e.g., due to mechanical- and/or exercise- stimulated 
glucose uptake) and/or stress responses [e.g., catecholamines (Cooney et al., 1985; Furler et al., 1991) 
and glucocorticoids (Pasieka and Rafacho, 2016)].  
  Here, we describe a protocol for a terminal intravenous ITT performed under pentobarbitone-induced 
anesthesia to assess insulin-stimulated glucose uptake into tissues of interest. The protocol can be 
performed with minimal delays between mice, making it amenable to assessing insulin action in large 
cohorts of animals. Intravenous administration of a bolus of insulin/tracer rapidly delivers insulin to 
tissues, minimizing the time between the start of the assay and initiation of insulin responses within 
tissues. Also, rapid equilibration of the 2-DOG tracer with the total blood glucose pool ensures that the 
tracer is immediately available for uptake into tissues. Alternative methods of insulin/tracer delivery (i.e., 
intraperitoneal injection, oral gavage) may result in delays or inconsistent insulin/tracer uptake into the 
central circulation. For example, in the case of IP injection, there may be a considerable delay before 
insulin reaches the circulation. These time lags may differ between mice or between injections, 
increasing experimental variability. Rapid and consistent tissue uptake is also particularly important 
when performing time-series experiments in live animals. Indeed, hepatic portal-vein administration of 
insulin has enabled the assessment of the time-resolved effects of insulin on the liver phosphoproteome 
(Humphrey et al., 2015). For oral gavage, 2-DOG may exhibit markedly different kinetics of appearance 
in the circulation compared to glucose since the sodium-dependent glucose transporters, which play a 
key role in oral glucose absorption, exhibit a strong preference for glucose (Bissonnette et al., 1996), 
and this may limit tracer availability to tissues during the assay. 
  In this protocol, mice are anesthetized with pentobarbitone and saline or insulin and radiolabeled 2-
DOG tracer administered via the hepatic portal vein. Insulin action in muscle and adipose tissues of 
interest can be assessed via Western blotting for insulin signaling intermediates or through measuring 
radiolabeled 2-DOG tracer accumulation as an index of glucose uptake.   
 
Materials and Reagents 
 
1. Pipette tips (e.g., Axygen, catalog numbers: T-1000-C, T-200-C) 
2. Cotton bud (e.g., McFarlane Medical Equipment, catalog number: 18049DE) 
3. 1.5 ml microfuge tubes (Axygen, catalog number: MCT-150-C) 
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4. 2.0 ml microfuge tubes (Eppendorf, catalog number: 0030120.094) 
5. 5 ml polystyrene tubes (SARSTEDT, catalog number: 60.9921.531) 
6. 0.5 ml Ultra-Fine Insulin Syringes (Becton Dickinson, catalog number: 230-45094) 
7. Masking tape (e.g., Lyreco, catalog number: 737.665) 
8. 96-well plates (Corning, catalog number: CLS2595) 
9. Carbon Steel, size 22 scalpel blades (Livingstone, catalog number: SBLDCL22) 
10. Chromatography columns (Bio-Rad, catalog number: 731-1550) 
11. 6 ml pony vial scintillation tubes (PerkinElmer, catalog number: 6000292) 
12. Adult mice (> 8 weeks old)  
Note: Ensure experiments using mice are carried with the approval of local ethics committee. 
Mice may be subjected to different dietary/exercise regimes or be knockout/transgenic lines for 
genes of interest. For knockout/transgenic lines we recommend using littermate controls.  
13. Double-distilled water (ddH2O) 
14. Bicinchoninic acid assay (BCA) protein assay kit (Thermo Fisher Scientific, catalog number: 
23225) 
15. Antibodies 
a. Anti-phospho-Thr308 Akt antibody (Cell Signaling Technology, catalog number: 9275) 
b. Anti-phospho-Ser473 Akt antibody (Cell Signaling Technology, catalog number: 4051) 
c. Anti-Akt antibody (Cell Signaling Technology, catalog number: 4685) 
16. Pentobarbitone (Lethabarb, Virbac, Australia) 
Note: Pentobarbitone may be a regulated substance. Ensure that use follows local regulations.  
17. Human insulin (Actrapid, Novo Nordisk) 
18. 0.9% Sodium Chloride Injection BP (Pfizer, catalog number: 158594) 
19. [3H]2-DOG (PerkinElmer, catalog number: NET328001MC) 
20. Accu-Chek performa Glucose Strips (Accu-Check II; Roche Diagnostics, catalog number: 
06454038) 
21. Liquid nitrogen 
22. AG1-X8 resin (Bio-Rad, catalog number: 140-1443) 
23. Ulitma Gold XR Scintillation fluid (PerkinElmer, catalog number: 6013119) 
24. Barium hydroxide (Sigma, catalog number: 433373) 
25. Dry ice 
26. 2.75% zinc sulfate solution (see Recipes) 
Zinc sulfate (ZnSO4) (Sigma, catalog number: 307491) 
27. Phosphorylated [3H]2-DOG elution buffer (see Recipes): 
a. Trifluoroacetic acid (Sigma, catalog number: 302031) 
b. NaCl (Sigma, catalog number: S7653) 
28. Western blot lysis buffer (see Recipes): 
a. HEPES (Sigma, catalog number: 54457) 
b. Sucrose (Sigma, catalog number: S8501) 
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c. EDTA (Sigma, catalog number: 03620) 
d. SDS (Sigma, catalog number: 71729) 
e. Protease inhibitors (Roche, cOmpleteTM, catalog number: 11697498001)  
f. Sodium pyrophosphate (Sigma, catalog number: 71501) 
g. Sodium orthovanadate (Sigma, catalog number: S6508) 
h. Sodium fluoride (Sigma, catalog number: S7920) 
 
Equipment 
 
1. Scalpel or surgical scissors (e.g., World Precision Instruments, catalog number: 501259-G) 
2. Pipettes (P20, P200, P1000) (e.g., Finnpipette F1 Pipettes, Thermo Fisher Scientific, catalog 
numbers: 4641050N, 4641080N, 4641100N) 
3. Echo-magnetic resonance imaging (MRI) scanner (Echo Medical Systems LLC, model: 
EchoMRI-4 in 1TM for Live Animals,) to assess mouse lean mass for insulin and pentobarbitone 
dosing 
4. Heat pads (Able Scientific, catalog number: ASCHP-RP) 
5. Blood glucometer (Roche Diagnostics, model: Accu-Check II) 
6. Mortar and pestle for tissue preparation (e.g., Maxwell & Williams, catalog number: AA1891) 
7. Ultrasonic tip-probe sonicator/homogenizer (Bendelin, model: Sonopuls) 
8. Refrigerated centrifuge (Thermo Fisher Scientific, model: Heraeus Fresco 21) 
9. Vortex (Ratek, model: VM1) 
10. Scintillation Counter (Beckman Coulter, model:LS6500) 
 
Software 
 
1. Microsoft Excel or GraphPad Prism 
 
Procedure 
 
A. Hepatic portal vein cannulation 
1. Determine mouse lean mass by ECHO-MRI according to the manufacturer’s instructions    
24-48 h prior to procedure.  
2. Remove food at least 2 h prior to starting experiment, depending on study requirements. 
3. Prepare a 96-well plate containing 75 μl 2.75% ZnSO4 per well for blood collection during the 
procedure. Prepare enough wells for collection of blood at 6 time points per mouse. Keep plate 
on ice throughout the procedure.  
4. Inject mice with 80 mg/kg lean mass (determined by ECHO-MRI) pentobarbitone 
intraperitoneally. Mice with increased adiposity may require more pentobarbitone, up to      
80 mg/kg body weight. See Videos 1 and 2. 
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Video 1. Intraperitoneal injection of pentobarbitone (This video was made at The University 
of Sydney. Procedures were approved by The University of Sydney Animal Ethics Committee 
under project # 2017/1274) 
 
 
Video 2. Intraperitoneal injection of pentobarbitone (close up) (This video was made at The 
University of Sydney. Procedures were approved by The University of Sydney Animal Ethics 
Committee under project # 2017/1274) 
 
5. Assess the quality of anesthesia using the toe-pinch reflex once the animal appears to be fully 
unconscious. When the mouse does not respond (approximately 15-20 min after injection), 
place animal on back (dorsal recumbency) on a heat pad (~30 °C) and secure the limbs to the 
surface using tape.  
Note: In the event that a mouse still has a toe-pinch reflex 20 min post-anesthetic, administer 
up to 20% more pentobarbitone and test for toe-pinch reflex again after 10 min. Euthanize 
mouse if still responsive. 
6. Cut the tip (1 mm) off the tail with a scalpel blade. Take a baseline blood glucose measurement 
from a drop of blood taken from the tail using a glucometer. Take 5 μl blood from the tail for 
scintillation counting to act as a background sample. Add this 5 μl blood to one well of a 96-well 
plate containing 75 μl 2.75% ZnSO4.  
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7. Make a 3 cm incision through the skin and peritoneum using a scalpel or surgical scissors across 
the midline and perpendicular up towards the rib cage to open the abdominal cavity. Avoid 
puncturing the diaphragm. See Video 3.  
8. Using a blunt sterile implement (e.g., cotton bud moistened with saline), carefully move the 
intestines to the right and the liver right and left medial lobes upward toward the ribcage to 
expose the hepatic portal vein and inferior vena cava (Figure 1A). See Video 3. 
 
 
Video 3. Surgery to access the hepatic portal vein (This video was made at The University 
of Sydney. Procedures were approved by The University of Sydney Animal Ethics Committee 
under project # 2017/1274)  
 
9. Using a 25-29 G insulin syringe, inject a bolus of saline (for non-insulin-stimulated glucose 
uptake) or insulin (for insulin-stimulated glucose uptake; 1 U/kg lean body mass) containing 5-
10 μCi [3H]2-DOG tracer into the hepatic portal vein (Figures 1A and 1B) or inferior vena cava 
if preferred. See Video 4 and Figure 1. 
Note: Ensure that use of radioactive material is performed following local guidelines and 
regulations, including appropriate use of protective equipment, safe work practices, cleaning of 
workspaces after experiments and waste disposal.  
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Video 4. Administration of saline to the hepatic portal vein. (This video was made at The 
University of Sydney. Procedures were approved by The University of Sydney Animal Ethics 
Committee under project # 2017/1274)  
 
10. The needle can either: 
a. Be rested to the side and left in the vein (Figure 1B). 
b. Be removed and a clamp applied to minimize bleeding.  
 
 
Figure 1. Hepatic portal vein cannulation in anesthetized mice. A. Location of the hepatic 
portal vein or inferior vena cava in mice. B. Picture of a Balb/c mouse during experiment where 
saline/insulin and tracer was injected via the hepatic portal vein and needle left in for the duration 
of the study. 
 
11. Measure blood glucose (from tail) and collect 5 μl blood (and add to ZnSO4 as in Step A6) per 
mouse to determine blood radioactivity after 2, 5, 10, 15, 20, and 30 min. 
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12. After 30 min, terminate the mouse by cervical dislocation and excise tissues of interest (e.g., 
quadriceps muscle, tibialis anterior muscle, gastrocnemius muscle, epididymal adipose tissue, 
inguinal adipose tissue, heart). Tissues should be snapped frozen in liquid nitrogen and stored 
at -80 °C until further analysis. Tissues can be weighed before or after freezing. 
Note: Mice should be culled at a time where blood tracer counts are still decreasing and have 
not plateaued. We typically perform 30 min ITTs.  
 
B. Western blot preparation 
1. Weigh out 50 mg epididymal white adipose tissue or muscle on dry ice, keeping the tissue frozen.  
2. Add 250 μl of Western Blot Lysis Buffer to frozen tissue and immediately homogenize by 
sonication (90% power, 3 x 10 s, allowing sample to cool between pulses). 
3. Centrifuge at 13,000 x g for 10 min at 12 °C.  
4. Remove the supernatant for muscle tissue, or carefully remove the infranatant for adipose tissue, 
being careful not to disturb the lipid layer.  
5. Determine protein concentration using BCA or similar protein assay and prepare samples for 
Western blot as per standard protocol using phospho-specific antibodies to signaling 
intermediates of interest (e.g., phospho-and total Akt) (Figure 2). 
Note: Care should be taken to ensure that waste from SDS-PAGE is disposed of according to 
local regulations since samples contain radioactivity. 
 
 
Figure 2. Assessment of insulin signaling in adipose tissue. Adipose tissue was excised 
from mice administered with saline or insulin. Phosphorylation of Akt at activating sites (Thr308 
and Ser473) was assessed by Western blotting with phospho-specific antibodies. Insulin 
increased Akt phosphorylation at both sites. 
 
C. Tracer disappearance and uptake 
1. To measure tracer disappearance from the blood, add 25 μl of a saturated Ba(OH)2 solution (in 
ddH2O) to wells containing blood samples in ZnSO4 (Step A5 above, final volume 105 μl). This 
deproteinizes the samples. Centrifuge the 96-well plate at 1,000 x g for 5 min to pellet 
precipitated protein and transfer 50 μl of the cleared sample to a scintillation vial and add 3 ml 
of scintillant. Count 3H DPM in each sample using a liquid scintillation counter.  
                 
9 
 
www.bio-protocol.org/e3146      
Vol 9, Iss 02, Jan 20, 2019 
DOI:10.21769/BioProtoc.3146 
 
  Copyright Fazakerley et al. 
This article is distributed under the terms of the Creative Commons Attribution License (CC BY 4.0). 
2. To measure tracer uptake into a tissue of interest, powder tissue in liquid nitrogen using a mortar 
and pestle and then weigh an aliquot of powder for analysis. Smaller tissues such as the soleus 
muscle can be homogenized according to Step C3 and do not require powdering.  
3. Homogenize ~40 mg tissue (as little as 10 mg soleus and EDL muscle can be used) in 1 ml 
ddH2O in a 1.5 ml tube by sonication (90% power, 3 x 10 s, allowing sample to cool between 
pulses) and centrifuge at 13,000 x g for 15 min. Collect supernatant (~800 μl) and transfer to a 
new 2.0 ml tube. Bring up volume to 2 ml with ddH2O. 
4. Prepare the phospho-2-DOG affinity elution columns by adding 1 ml AG1-X8 resin diluted in 
ddH2O (70% volume resin) to a 0.8 x 4 cm chromatography column using a wide-bore pipette 
tip (e.g., P1000 tip cut 5 mm from the tip using a scalpel blade to increase the aperture).  
5. Place 5 ml tubes below the columns and add 1 ml of the supernatant to the columns followed 
by three 1 ml washes with ddH2O. 
6. Place new scintillation vials below the columns and add 1 ml of the elution buffer (see Recipes 
below) to columns followed by another 1 ml of elution buffer.  
7. Add 3 ml scintillation fluid (PerkinElmer) to the scintillation vials, vortex thoroughly, and measure 
3H DPM in each sample using a liquid scintillation counter to quantify [3H]2-DOG-6-P. 
 
Data analysis 
 
The aim of data analysis is to normalize for the amount of tracer delivered to each mouse and 
available for uptake into tissues, and the amount of tissue analyzed. Methods for normalizing such 
data have been discussed extensively elsewhere (Sokoloff et al., 1977; Goodner et al., 1980; Hom 
et al., 1984; Cooney et al., 1985; Kraegen et al., 1985).  
  We describe two methods below: 1) the data are normalized to tracer availability in the blood to 
calculate the amount of tracer taken into the tissue of interest as a proportion of the amount of tracer 
available to the tissue, and 2) approximate an index of glucose uptake into tissues by using DPM 
and blood glucose to calculate a specific activity (DPM/mol glucose). In each case, data can be 
expressed per unit weight and/or protein/DNA content of the analyzed tissue.  
 
Note: The methods described below use an area under the curve (AUC) calculation to normalize for 
tracer availability to tissues. This method works best if mice are culled when blood tracer counts are 
decreasing and have not plateaued. We typically perform 30 min ITTs. 
1. To calculate tracer 2-DOG clearance into specific tissues as a proportion of total 2-DOG 
available to the tissue:  
This calculation assumes that the 2-DOG tracer measured by a tail bleed is indicative of tracer 
available in the interstitial space for uptake into the tissue.   
  First, extrapolate DPM per 5 μl to 1 ml to yield DPM/ml. Since the tracer will disappear from 
the blood by an exponential decay, calculate the AUC by fitting the DPM/ml at measured time 
points to a single exponential function, and integrate this function over the experimental period. 
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This estimates the change in blood DPM/ml throughout the experiment (DPM/ml·min). This AUC 
value provides a normalization factor that takes into account differences in tracer availability 
between mice.  
  Tissue DPMs can be normalized using this AUC value to calculate the proportion of available 
tracer taken up into the tissue. This can be further normalized to the weight of tissue analyzed 
(g). The final units are: 2-DOG clearance (ml/min/g). Data normalized using this method are 
presented in Figures 3A and 3B. These data show insulin-stimulated 2-DOG clearance into 
muscle and adipose tissues, but not into brain (Figure 3A) and that feeding mice a diet high in 
fat and sucrose leads to impaired insulin-stimulated 2-DOG clearance into epididymal adipose 
tissue and quadriceps muscle (Figure 3B). 
2. To obtain a tissue-specific index of glucose uptake: 
The blood glucose concentration during this assay is non-steady-state. This calculation aims to 
take into account differences in blood glucose over the course of the experiment and 
approximate glucose uptake into tissue. This calculation assumes that there is no discrimination 
between 2-DOG and glucose at the glucose transporter and therefore the rate of [3H]2-DOG 
accumulation in tissue is equivalent to the rate of glucose uptake into tissue (Ferre et al., 1985). 
Since the kinetics of 2-DOG and glucose uptake may differ, we advise referring to 2-DOG 
accumulation as a “glucose uptake index”. 
  First calculate the AUC for blood DPM (as above by exponential curve fitting; DPM/ml·min) 
and blood glucose during the ITT (by the trapezoidal method; μmol/ml·min). The average 
specific activity of 2-DOG in the blood can be calculated by dividing the blood DPM AUC by 
blood glucose AUC (DPM/μmol). Tissue DPM can then be converted to an index for the rate of 
glucose uptake by dividing by the average specific activity, and further normalized to the weight 
of tissue analyzed (g) and expressed per min or h. The final units are: Glucose uptake index 
(μmol/g/h). Data normalized using this method are presented in Figure 3B. These data show 
that feeding mice a high fat high sucrose diet for 14 d lowers the insulin-stimulated glucose 
uptake index in epididymal adipose tissue and quadriceps muscle (Figure 3C). 
 
 
Figure 3. 2-DOG uptake into tissues. A. 2-DOG clearance into indicated tissues was assessed 
in C57Bl/6J mice following saline or insulin administration (Epi; Epididymal, Subcut; 
subcutaneous/inguinal, EDL; Extensor digitorum longus). Adipose and muscle tissues exhibited 
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insulin-responsive 2-DOG clearance. B and C. Insulin-stimulated 2-DOG clearance (B) or 
glucose uptake index (C) for epididymal white adipose tissue (WAT) (left inset) and quadriceps 
muscle (right inset) in C57Bl/6J mice fed a chow diet or high fat high sucrose diet (HFHSD).  
*P < 0.05 versus mice fed a chow diet, Student’s t-test, n = 6-7. Data in B and C were 
recalculated from Fazakerley et al. (2018a). 
 
Recipes 
 
1. 2.75% zinc sulfate solution  
100 ml of 2.75% zinc sulfate contains 4.44 g zinc sulfate in ddH2O 
2. Phosphorylated [3H]2-DOG elution buffer 
Low pH, high salt solution (e.g., 1% Trifluoroacetic acid, 2 M NaCl) 
100 ml of elution buffer contains 1 ml 100% Trifluoracetic acid and 11.69 g NaCl in ddH2O 
3. Western blot lysis buffer 
10 mM HEPES, pH 7.4 
250 mM sucrose 
1 mM EDTA 
2% SDS 
Protease and phosphatase inhibitors (1 mM sodium pyrophosphate, 2 mM sodium 
orthovanadate, 10 mM sodium fluoride) 
We advise making 10x stocks of HEPES pH 7.4, sucrose, EDTA and SDS.  
10 ml of lysis buffer contains, 23.8 mg HEPES, 855.6 mg sucrose, 2.9 mg EDTA, 576.8 mg SDS, 
1x Roche cOmpleteTM protease inhibitors, 1 mM sodium pyrophosphate, 2 mM sodium 
orthovanadate, 10 mM sodium fluoride. Adjust the solution pH to 7.4 
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